---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-033456"
form_type: "8-K"
ticker: "APYX"
cik: "0000719135"
company_name: "Apyx Medical Corp"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-17T00:05:19.747707+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apyx Medical Q3 rev $12.9M (+12% YoY); net loss $2.0M; raises FY guidance to $50.5-52.5M

## Summary
- Total revenue $12.9M (+12% YoY); Surgical Aesthetics $11.1M (+19% YoY).
- Net loss attributable to stockholders $2.0M ($0.05/sh) vs $4.7M loss in Q3 2024.
- Adjusted EBITDA loss improved 96% to $0.1M from $2.4M in Q3 2024.
- FY2025 revenue guidance raised to $50.5-52.5M (prev $50-52M); Surgical Aesthetics segment guided at $43-45M.
- Initiated full U.S. commercial launch of AYON Body Contouring System; submitted 510(k) for power liposuction label expansion.

## SEC filing metadata
- accession: 0001437749-25-033456
- form_type: 8-K
- ticker: APYX
- cik: 0000719135
- company_name: Apyx Medical Corp
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/0001437749-25-033456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/719135/000143774925033456/apyx20250816_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-033456
- JSON: https://secwatch.observer/filing/0001437749-25-033456.json
- Plain text: https://secwatch.observer/filing/0001437749-25-033456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.